Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity
Reads0
Chats0
TLDR
Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity as discussed by the authors has been shown to be a significant risk factor for nonalcoholic liver disease.Abstract:
Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activityread more
Citations
More filters
Journal ArticleDOI
Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals.
K. Chan,Tiffany Jia Ling Koh,An Tang,Jin Siang. Quek,Jie Ning Yong,Phoebe Wen Lin Tay,Darren Jun Hao Tan,Wen Hui Lim,Snow Yunni Lin,Daniel Q. Huang,Mark Y. Chan,Chin Meng Khoo,Nicholas Chew,Apichat Kaewdech,Naichaya Chamroonkul,Yock Young Dan,Mazen Noureddin,Mark D. Muthiah,Mohammed Eslam,Cheng Han Ng +19 more
TL;DR: While exploration of the pathogenic basis of fatty liver disease without metabolic dysregulation is required, the emphasis on management of concomitant metabolic disease in MAFLD can improve multidisciplinary efforts in managing the complex disease.
Journal ArticleDOI
The Spectrum and Impact of Metabolic Dysfunction in MAFLD. A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals.
K. Chan,Cheng Han Ng,Clarissa Fu,Jin Siang. Quek,Gwyneth Kong,Yi Jie Goh,R. Zeng,Michael Tseng,Manik Aggarwal,B. Nah,Douglas Chee,Z. Wong,Sitong Zhang,Jiong-Wei Wang,Nicholas Chew,Yock Young Dan,Mohammad S. Siddiqui,Mazen Noureddin,Arun J. Sanyal,Mark D. Muthiah +19 more
TL;DR: In this paper , the authors examined the prevalence, clinical characteristics, and differences in outcomes of metabolically healthy (MH) and metabolically unhealthy (MU) individuals at the population level and used multivariate logistic regression analysis to obtain odds ratios for the estimation of events.
Journal ArticleDOI
Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease
Mirolyuba Ilieva,James Dao,Henry E. Miller,Jens Hedelund Madsen,Alexander J.R. Bishop,Sakari Kauppinen,Shizuka Uchida +6 more
TL;DR: To demonstrate the functional importance of lncRNAs in the liver, loss-of-function experiments were performed for one NAFLD-related lncRNA, LINC01639, which showed that it is involved in the regulation of genes related to apoptosis, TNF/TGF, cytokine signaling, and growth factors as well as genes upregulated inNAFLD.
Journal ArticleDOI
Liver Steatosis: A Marker of Metabolic Risk in Children
TL;DR: This review aims to share the latest scientific knowledge on MAFLD in children in an attempt to offer novel insights into the complex dynamics underlying this condition, focusing on the novel molecular aspects.
Journal ArticleDOI
Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications
TL;DR: A nomenclature of metabolic associated fatty liver disease (MAFLD) with a new definition was proposed in 2020 instead of the previous "non-alcoholic fatty liver diseases" (NAFLD), whether it better coheres with the clinical demand remains controversial as mentioned in this paper .
References
More filters
Journal ArticleDOI
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami,Jianjiong Gao,Ugur Dogrusoz,Benjamin Gross,Selcuk Onur Sumer,Bulent Arman Aksoy,Anders Jacobsen,Caitlin Byrne,Michael Heuer,Erik G. Larsson,Yevgeniy Antipin,Boris Reva,Arthur P. Goldberg,Chris Sander,Nikolaus Schultz +14 more
TL;DR: The cBio Cancer Genomics Portal significantly lowers the barriers between complex genomic data and cancer researchers who want rapid, intuitive, and high-quality access to molecular profiles and clinical attributes from large-scale cancer genomics projects and empowers researchers to translate these rich data sets into biologic insights and clinical applications.
Journal ArticleDOI
Diet rapidly and reproducibly alters the human gut microbiome
Lawrence A. David,Corinne F. Maurice,Rachel N. Carmody,David B. Gootenberg,Julie E. Button,Benjamin E. Wolfe,Alisha V. Ling,A. Sloan Devlin,Yug Varma,Michael A. Fischbach,Sudha B. Biddinger,Rachel J. Dutton,Peter J. Turnbaugh +12 more
TL;DR: Increases in the abundance and activity of Bilophila wadsworthia on the animal-based diet support a link between dietary fat, bile acids and the outgrowth of microorganisms capable of triggering inflammatory bowel disease.
Journal ArticleDOI
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
Zobair M. Younossi,Zobair M. Younossi,Aaron B. Koenig,Dinan Abdelatif,Yousef Fazel,Linda Henry,Mark Wymer,Mark Wymer +7 more
TL;DR: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous, and random‐effects models were used to provide point estimates of prevalence, incidence, mortality and incidence rate ratios.
Journal ArticleDOI
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo,Julia Kozlitina,Julia Kozlitina,Chao Xing,Alexander Pertsemlidis,David Cox,Len A. Pennacchio,Len A. Pennacchio,Eric Boerwinkle,Jonathan C. Cohen,Helen H. Hobbs +10 more
TL;DR: Variation in PNPLA3 contributes to ancestry-related and inter-individual differences in hepatic fat content and susceptibility to NAFLD.
Journal ArticleDOI
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal,Naga Chalasani,Kris V. Kowdley,Arthur J. McCullough,Anna Mae Diehl,Nathan M. Bass,Brent A. Neuschwander-Tetri,Joel E. Lavine,James Tonascia,Aynur Unalp,Mark L. Van Natta,Jeanne M. Clark,Elizabeth M. Brunt,David E. Kleiner,Jay H. Hoofnagle,Patricia R. Robuck +15 more
TL;DR: Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes, and significant benefits of pioglitazone were observed for some of the secondary outcomes.